New hope for tough breast cancer: trial tests promising drug duo
NCT ID NCT07111832
Summary
This study is testing whether a new combination of two drugs (SHR-A1811 and SHR-1316) works better than the current standard treatment for advanced triple-negative breast cancer that has spread or returned. It's for women whose cancer tests positive for a marker called PD-L1. The main goal is to see if the new combination can keep the cancer from growing for a longer time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PD-L1-POSITIVE LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital，Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.